跳至主要内容
临床试验/NCT03629015
NCT03629015撤回1 期

The Safety Study of Stemchymal® (Allogeneic Adipose-Derived Mesenchymal Stem Cells) Treating on Acute Liver Failure - An Open-Label, Single-Center Phase I Trial

Steminent Biotherapeutics Inc.1 个研究点 分布在 1 个国家开始时间: 2018年10月1日最近更新:
适应症

试验速览

阶段
1 期
状态
撤回
试验地点
1
主要终点
The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)

研究概览

简要总结

To investigate the safety of Stemchymal® via intravenous (IV) infusion in acute liver failure (ALF) and acute on chronic liver failure (ACLF) patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ALF or ACLF patients.
  • Subjects are between 20 and 70 years of age.
  • MELD scores meet 17 ≤ MELD ≤
  • Subjects who had completed signing informed consent.

排除标准

  • Subjects who had been enrolled in any other cell therapy within six months.
  • Females with a positive pregnancy test result.
  • Subjects have contraindication for liver transplantation.
  • Subjects with psychiatric illnesses.
  • Subjects who are diagnosed as active tuberculosis (TB).
  • Subjects with immunological disorders (e.g. autoimmune hepatitis) or using immunosuppressive drugs (e.g. steroid for immunosuppression) within six months prior to screening visit.
  • Subjects with unstable illnesses or contraindication for this clinical trial according to investigator's judgment.

结局指标

主要结局

The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR)

时间窗: 12 months

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验